October 24, 2023
1 min watch
Save
VIDEO: ONL1204 demonstrates promising results in geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW YORK — In this Healio Video Perspective from OSN New York’s Disruptive Innovations Symposium, David Esposito, CEO of ONL Therapeutics, discusses results of ONL1204 in geographic atrophy.
“It’s a small peptide delivered via [intravitreal] injection, and we’re across three clinical programs: one in geographic atrophy, one in open-angle glaucoma and one in retinal detachment,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Esposito reports being the CEO of ONL Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.